Trial NCT01607645

View at ClinicalTrials.gov 
Org. Study IDs: 2588.00
Secondary IDs: NCI-2012-00769 P30CA015704

Last trial update was posted on 2017-03-31

MeSH Interventions

Azacitidine Cytarabine Decitabine Idarubicin

MeSH Conditions

Anemia, Refractory Anemia, Refractory, with Excess of Blasts Leukemia Leukemia, Erythroblastic, Acute Leukemia, Megakaryoblastic, Acute Leukemia, Monocytic, Acute Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myelomonocytic, Acute Myelodysplastic Syndromes

Other Conditions

Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia Refractory Anemia With Excess Blasts

Stopping Reasons

The study was terminated early because there were other competing protocols.

Limitations And Caveats

Early termination due to similar competing protocol, which made statistical evaluation of primary endpoint and any meaningful evaluation of secondary time points not feasible.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID